Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Oral Administration. Found 26 abstracts

no pagination
Geynisman DM, Meeker CR, Doyle JL, Handorf EA, Bilusic M, Plimack ER, Wong YN. Provider and patient burdens of obtaining oral anticancer medications. The American journal of managed care. 2018 Apr;24(4):e128-e133.
Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DY, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. J Clin Oncol. 2017 Sep 10;35(26):2993-3001.
Fan F, Yuan Z, Qin X, Li J, Zhang Y, Li Y, Yu T, Ji M, Ge J, Zheng M, Yang X, Bao H, Cheng X, Gu D, Zhao D, Wang J, Sun N, Chen Y, Wang H, Wang X, Parati G, Hou F, Xu X, Wang X, Zhao G, Huo Y. Optimal Systolic Blood Pressure Levels for Primary Prevention of Stroke in General Hypertensive Adults: Findings From the CSPPT (China Stroke Primary Prevention Trial). Hypertension (Dallas, Tex : 1979). 2017 Apr;69(4):697-704.
Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schonland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017 Aug 03;130(5):597-605.
Weinberg DS, Lin JE, Foster NR, Della'Zanna G, Umar A, Seisler D, Kraft WK, Kastenberg DM, Katz LC, Limburg PJ, Waldman SA. Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. Cancer prevention research (Philadelphia, Pa). 2017 Jun;10(6):345-54.   PMCID: PMC5758862
Boushra M, Tous S, Fetih G, Korzekwa K, Lebo DB, Xue HY, Wong HL. Development and evaluation of viscosity-enhanced nanocarrier (VEN) for oral insulin delivery. International journal of pharmaceutics. 2016 Sep 10;511(1):462-72.
Boushra M, Tous S, Fetih G, Xue HY, Tran NT, Wong HL. Methocel-Lipid Hybrid Nanocarrier for Efficient Oral Insulin Delivery. Journal of pharmaceutical sciences. 2016 May;105(5):1733-40.
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). 2016 May 14;387(10032):2008-16.   PMCID: PMC4878938
Lounsbury N, Mateo G, Jones B, Papaiahgari S, Thimmulappa RK, Teijaro C, Gordon J, Korzekwa K, Ye M, Allaway G, Abou-Gharbia M, Biswal S, Childers W. Heterocyclic chalcone activators of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) with improved in vivo efficacy. Bioorganic & medicinal chemistry. 2015 Sep;23(17):5352-9.
Zhang Y, Zhao J, Li R, Lau WB, Yuan YX, Liang B, Li R, Gao EH, Koch WJ, Ma XL, Wang YJ. AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings. Am J Physiol Endocrinol Metab. 2015 Aug;309(3):E275-82.   PMCID: PMC4525114
Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, Cohen RB. Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol. 2014 Oct;32(28):3103-10.
Shen C, Chien CR, Geynisman DM, Smieliauskas F, Shih YC. A review of economic impact of targeted oral anticancer medications. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):45-69.
Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Apr;67(4):945-54.   PMCID: PMC3026871
Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L, Pluda JM, Figg WD, Krown SE, Dezube BJ. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol. 2002 Jan;20(1):153-9.
Cohen SJ, Leichman CG, Yeslow G, Beard M, Proefrock A, Roedig B, Damle B, Letrent SP, DeCillis AP, Meropol NJ. Phase I and pharmacokinetic study of once daily oral administration of s-1 in patients with advanced cancer. Clin Cancer Res. 2002 Jul;8(7):2116-22.
Hudes G. Boosting bioavailability of topotecan: what do we gain?. J Clin Oncol. 2002 Jul;20(13):2918-9.
Marsh JC, Catalano P, Huang J, Graham DL, Cornfeld MJ, O'Dwyer PJ, Benson AB. Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. Clin Colorectal Cancer. 2002 May;2(1):43-50.
Bookman MA. Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2001 Jan;11 Suppl 1:42-51.
Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A, Rogatko A, Babb J, Minnitti C, Flinker D, Gillon T, Hudes G. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology. 2001 Jul;58(1):59-64.
Langer CJ. The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancer. Lung Cancer. 2001 Nov;34(2):297-303.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Oral Administration

Oral Administration administration & dosage drug therapy Female Male therapeutic use Aged Antineoplastic Agents drug effects metabolism adverse effects 80 and over Aged Middle Aged Adult Human Treatment Outcome pharmacokinetics Drug Administration Schedule antagonists & inhibitors pharmacology Drug Dose-Response Relationship pathology Antineoplastic Combined Chemotherapy Protocols analogs & derivatives Disease-Free Survival Middle Age Neoplasms chemically induced Caco-2 Cells genetics Drug Delivery Systems Kidney Neoplasms methods agonists etiology prevention & control physiology Non-US Gov't Support mortality Type I DNA Topoisomerases Prostatic Neoplasms Young Adult Follow-Up Studies effects Paclitaxel Cell Survival complications Survival Rate secondary chemistry Insulin Time Factors Nanoparticles Double-Blind Method Lung Neoplasms US Gov't Support-PHS Drug Carriers Renal Cell Carcinoma physiopathology Area Under Curve Neoplasm Drug Resistance Drug Combinations Colorectal Neoplasms Biological Availability Oxidative Stress Random Allocation Tegafur Maximum Tolerated Dose Enzyme Inhibitors Topotecan Nausea Uracil Survival Analysis adverse Ki-67 Antigen Sunitinib China Prior Authorization Socioeconomic Factors epidemiology Cyclic GMP Gelatinase B Intestinal Absorption Drug Industry blood Disease Progression Rats toxicity Enterotoxin Receptors Phenylurea Compounds Leucovorin Microfilament Proteins Adiponectin Receptors Breast Neoplasms Pharmaceutical Solutions secretion Clinical Trials Cell Line Aurora Kinases Carcinoma Nonparametric Statistics P-Glycoprotein stability Non-Small-Cell Lung Carcinoma Natriuretic Peptides Encapsulation efficiency Health Services Accessibility Half-Life Pharmaceutical Services Insurance Liver Neoplasms Colon Rectum Gastrointestinal Diseases Incidence Piperidines Tumor Biomarkers Disorders of Excessive Somnolence Keap1 Tetracycline Sprague-Dawley Rats Edema Primary Prevention Endothelial Growth Factors Heme Oxygenase-1 Preclinical Drug Evaluation Amyloidosis Phosphoproteins peptides goal blood pressure Myocardial Ischemia Phosphorylation Methylcellulose Randomized Controlled Trials Adenocarcinoma reperfusion injury statistics & numerical data Solid lipid nanoparticles Combination Drug Therapy Retrospective Studies Antineoplastic Antimetabolites ATP-Binding Cassette Transporters Prognosis Fluorouracil Peptide Thiazoles Liposomes Protein Kinase Inhibitors Gastrointestinal Hormones stroke Benzazepines
Last updated on Friday, January 03, 2020